Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aims of this trial are to evaluate the efficacy of bendamustin in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-baesd chemotherapy and to assess the treatment of toxicity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically confirmed metastatic or non-resectable soft tissue sarcoma
Evidence of progression or relapse after an anthracycline-based and/ or ifosfamide-based chemotherapy
At least 1 bidimensionally measurable tumor lesion according to RECIST criteria
No previous radiation therapy on the only measurable lesion
Willingness to receive regular follow-up
Life expectancy more than 3 months
ECOG status >= 2
Patients aged 18 years and beyond
leucocytes > 2500/µl, thrombocytes > 75000/µl)
Serum creatine < 1,5 times the upper limit of normal value, GFR > 60/ml
Written patient informed consent
Ability to give informed consent
Previous or concurrent radiation of the index lesion (radiation of single lesion is allowed if not the index lesion)
Insufficient liver function (bilirubin > 1.5 the upper limit of normal, prolongation of PT and aPTT > 1.5 the upper limit of normal; ASAT and ALAT > 3 the upper limit of normal (patients with liver metastases ASAT and ALAT > 5 the upper limit of normal)
Prior therapy with Bendamustin hydrochloride
Prior malignancies (other than adequately treated carcinoma in situ (CIS) of the cervix, bladder urothelium, basal cell carcinoma or adenoma of the colon including pTIS,pTIN), unless treated with curative intent and without evidence of disease > 5 years